NeuroNEXT News

2024 Clinical Trials Methodology Course Call for Applications - Due March 4, 2024

We are pleased to announce the continuation of the NINDS Clinical Trials Methodology Course (CTMC). We are currently accepting applications for the 2024 cohort. The overarching goal of the CTMC is to help investigators develop scientifically rigorous, yet practical clinical trial protocols. Our focus is on investigators who have not previously designed their own prospective, interventional clinical trials.  Applicants proposing large, multi-center trials will also be considered this year.

Notice of Information of Intent to Publish Research Opportunity Announcements for the “NeuroNEXT Clinical Trials: Stage 1 (Preliminary) and Stage 2 (Protocol) Applications (OT2)”

NOI for 2 new ROAs will be issued for NeuroNEXT Clinical Trials: Stage 1 Preliminary Application and Stage 2 Protocol Application will replace the current Notice of Funding Opportunity 'NeuroNEXT Clinical Trials (U01 Clinical Trial Optional) PAR-21-223' expiring on March 06, 2024.

NOI: https://grants.nih.gov/grants/guide/notice-files/NOT-NS-24-045.html

Gene Therapy Consortium ROAs Published

The ROAs for the Gene Therapy Consortium were published on December 4, 2023.  Please find the links below.  The submissions will be accepted starting on December 28, 2023 and the submission deadline is rolling.

Dr. Rossignol to Present as Part of 2022 GNEM Symposium Speaker Series

External Source: 

Dr. Francis Rossignol of hte NIH National Human Genome Research Institute (NHBRI) will present as part of theGNEM Symposium Speaker Series presented by the Neuromuscular Disease Foundation. His talk, entitled "ManNAc As A Potential Therapy for GNE Myopathy - Advances and Future Directions" will include discussion of NN109. This talk is free of charge and available virtually.

CTMC: 2021 Call for Applications

External Source: 

We are pleased to announce that the NINDS Clinical Trials Methodology Course (CTMC) is accepting applications for the 2021 cohort. The overarching goal of the CTMC is to help investigators develop scientifically rigorous, yet practical clinical trial protocols. Our focus is on investigators who have not previously designed their own prospective, interventional clinical trials.   

Course: 

NeuroNEXT 2020 Annual Meeting

NeuroNEXT Leadership would like to thank everyone for another successful annual meeting! We were able to celebrate several milestones in our virtual format, including: 

Update: Clinical Trials Methodology Course 2020

External Source: 

A message from the Executive Committee of the Clinical Trials Methodology Course (CTMC): 

Due to the global COVID-19 (Coronavirus) pandemic and the number of uncertainties that accompany such a health crisis, the Clinical Trials Methodology Course (CTMC) Executive Committee has decided to postpone the Course until next year.

NeuroNEXT Response to COVID 19

A message from Merit Cudkowicz and Christopher Coffey, March 18, 2020: 

Dear NeuroNEXT PIs and Coordinators,

 We would like to share some updates regarding NeuroNEXT Network response to the evolving COVID-19 crisis.

Call for INC Pilot Award Applications!

The INC Pilot/Feasibility Core is now accepting applications for Pilot Awards. The goal of the INC Pilot Awards is to support investigators wishing to perform single or multi-site projects that will advance the diagnosis, clinical trial readiness, management, and/or treatment of CMT. Both senior investigators wishing to expand their research into new directions and Junior INC investigators are encouraged to apply.

NeuroNEXT 2019 Annual Meeting Slides Available

The slide presentation from the 2019 NeuroNEXT Annual Meeting in Pittsburgh, PA October 28-29 are now available on the NeuroNEXT private website. They can be accessed under Network Materials > Annual Meetings. Thanks to everyone for a successful meeting!